Clinical trial
Enzastaurin for Patients With Metastatic Colorectal Cancer
NCT00192114 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00192114 |
|---|---|
| Title | Enzastaurin for Patients With Metastatic Colorectal Cancer |
| Official title | A Phase 2 Study of Oral Enzastaurin HCl in Patients With Metastatic Colorectal Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colonic Neoplasms |
| Intervention type | Drug |
| Interventions | Enzastaurin HCl |
| Enrollment | 28 |
| Start date | Aug 1, 2005 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Sep 19, 2005 |
| Last update posted | Aug 6, 2020 |
| Countries | Denmark, Sweden |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: